Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYOTO-FINE finerenone dose-titration study in CKD and type 2 diabetes
jRCTs051260027Recruiting
- Sponsor
- Bayer
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of finerenone in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM), sponsored by Bayer. Primary endpoint: Change in UACR from baseline to week 24. Started Jun 2026; status: recruiting.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051260027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260027.